|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Molecular & Cellular Proteomics 3:257-265, 2004.
© 2004 by The American Society for Biochemistry and Molecular Biology, Inc.




,¶
From the
Department of Biological Sciences, University of Calgary, Calgary, Alberta T2N 1N4, Canada; and
Medical Research Council Protein Phosphorylation Unit, School of Life Sciences, University of Dundee, Dundee DD1 5EH, United Kingdom
| ABSTRACT |
|---|
|
|
|---|
1,
2, ß, and
1, plus the A
and several of the B and B' subunits that are complexed to PP2A. Other proteins enriched on the microcystin matrix include the spliceosomal proteins known as the U2 snRNPs SAP145 and SAP155 and the U5 snRNPs p116 and p200, myosin heavy chain, and a nuclear PP1 myosin-targeting subunit related to M110. The putative RNA binding protein ZAP was also established as a nuclear PP1 binding protein using the criteria of co-purification with PP1 on microcystin-Sepharose, co-immunoprecipation, binding PP1 in an overlay assay, and presence of a putative PP1 binding site (KKRVRWAD). These results further support a key role for protein phosphatases in several nuclear functions, including the regulation of pre-mRNA splicing.
1 resides primarily in the nucleolar compartment, PP1
in the nucleoplasmic fraction, and PP1ß in both nuclear compartments (7). Several nuclear PP1-targeting subunits have now been identified (69). The two most-abundant nuclear PP1 binding subunits, p99 or PNUTS and nuclear inhibitor PP1 (NIPP-1), are RNA-binding proteins that likely play a role in pre-mRNA splicing (911). Both proteins contain the PP1 binding motif R/K-V/I-X-F/W that was originally identified from studies on the glycogen and myosin PP1-targeting subunits (1216). This motif has been shown to be present in nearly all PP1-associating proteins. Due to the number of nuclear events controlled by phosphorylation/dephosphorylation, there undoubtedly exist many more, as yet unidentified proteins that target or localize nuclear protein phosphatases. Here, we have done an extensive examination of the mammalian nucleus for protein phosphatase-associated proteins by utilizing the protein phosphatase affinity matrix microcystin-Sepharose. This matrix has been used previously to successfully purify other protein phosphatase-targeting subunit complexes (12, 13). Using a combination of affinity chromatography and mass spectrometry, we have identified many new proteins localized to protein phosphatase complexes, and here we show many more PP1 binding proteins exist in the nucleus than have been previously demonstrated. This work implicates protein phosphatases as regulators of many nuclear events. | EXPERIMENTAL PROCEDURES |
|---|
|
|
|---|
1 was expressed and purified as described previously (17) and dialyzed into 25 mM NaHCO3, pH 7.5, 200 mM KCl, 50% (v/v) glycerol, 0.1% (v/v) 2-mercaptoethanol (2-ME) for storage. The human PP1
1 clone was kindly provided by S. Shenolikar (Duke University), transfected into Escherichia coli BL21 (DE3), and the protein expressed (18) and purified on microcystin-Sepharose (12).
Preparation of Nuclear Extracts from Rat Liver
Male Wistar rats were sacrificed, and livers were removed and Dounce homogenized in 2 volumes of TKM (50 mM Tris-HCl, pH 7.5, 25 mM KCl, 5 mM MgCl2), 0.25 M sucrose, 0.1% (v/v) 2-ME, and filtered through two layers of mira-cloth (Calbiochem, La Jolla, CA). Nuclei were pelleted by centrifugation at 2,400 x g for 10 min in a Sorval SLA-1500 rotor and resuspended in 3 ml TKM, 0.25 M sucrose/10 g tissue, and mixed with 2 volumes of TKM, 2.3 M sucrose at 4 °C. Nuclei were layered on 10 ml of TKM, 2.3 M sucrose, and centrifuged at 82,800 x g in a Beckman SW 27 rotor for 1 h at 4 °C. The isolated nuclei were resuspended in TKM, 0.25 M sucrose plus 0.5% (v/v) Triton X-100, and put on ice for 10 min to dissolve nuclear membranes. The nuclei were repelleted by centrifugation at 2,000 x g for 5 min at 4 °C in a Sorval SS-34 rotor and then resuspended in buffer A (50 mM Tris-HCl, pH 7.5, 10 mM EDTA, 0.1% (v/v) 2-ME, 0.5 mM phenylmethylsulfonyl fluoride (PMSF), 1 mM benzamidine, and 5 µg/ml leupeptin). After 10 min on ice, the nuclei were Dounce homogenized, and after centrifugation at 7,800 x g for 5 min at 4 °C in a Sorval SS-34 rotor the supernatant was retained and the nuclear pellet rehomogenized in buffer B (50 mM Tris-HCl, pH 7.5, 0.42 M NaCl, 0.1 mM EGTA, 5% (v/v) glycerol, 0.1% (v/v) 2-ME, 0.5 mM PMSF, 1 mM benzamidine, and 5 µg/ml leupeptin). After centrifugation at 7,800 x g for 10 min at 4 °C in a Sorval SS-34 rotor, this extracted protein was pooled with the first supernatant and the pellet re-extracted with buffer B, clarified as above, and all the supernatant fractions pooled and designated the nuclear extract (NE).
Microcystin-Sepharose Chromatography
Extracted nuclear proteins (
1 mg protein per gram liver tissue) were incubated end over end with 1 ml of microcystin-Sepharose matrix prepared as described (12) and previously equilibrated in buffer C (50 mM Tris-HCl, pH 7.5, 0.1 mM EGTA, 5% (v/v) glycerol, 0.1% (v/v) 2-ME). After 1 h, the column was washed with buffer C and 0.3 M NaCl until essentially no protein was eluting off the column (250 column volumes). Proteins were eluted by incubation for 30 min with 3 M sodium isothiocyanate and then the first 20 ml was collected. Protein was dialyzed extensively in buffer C plus 0.5 mM PMSF and 1 mM benzamidine, concentrated in a centriprep 10 (Millipore, Bedford, MA) and centricon 10 (Millipore) to 50 µl, then boiled in SDS. A control matrix was prepared by blocking CH-Sepharose (Pharmacia, Piscataway, NJ)-reactive groups with Tris, as described by the manufacturer. In experiments where the control matrix was used, the pooled nuclear extract was divided in half and loaded separately onto 1-ml microcystin and control columns. Both matrices were washed and eluted identically and in parallel to allow direct comparison of eluted proteins. A typical preparation with 175 g of tissue resulted in the elution of 45 µg of protein from the microcystin-Sepharose matrix and 15 µg from the control matrix. In some cases, after elution with 3 M thiocyanate, the affinity matrix was washed with buffer C and warmed to room temperature, then incubated with 2% (w/v) SDS for 5 min and eluted with further SDS. The first 4 ml collected was concentrated with a speedi-vac concentrator to 500 µl and boiled in SDS.
Western Blotting and Immunoprecipitation
Monoclonal antibodies to PP1 and PP2A catalytic subunits were purchased from Transduction Laboratories (Lexington, KY) and were used at 0.25 µg/ml. The anti-talin antibody was obtained from Sigma and used at a 1,000-fold dilution. An anti-peptide antibody to ZAP was generated by coupling the ZAP peptide 1366EKITDESGHLAERALNR1382 to KLH and performing injections as described in Tran et al. (19) and were affinity purified on a peptide affinity column (19). Affinity-purified antibodies to the smooth muscle myosin-targeting subunits M110 and M20 were provided by P. Cohen (University of Dundee). Other antibodies were kindly provided by the following individuals and used as described in the indicated references. NIPP-1 and p99 (L. Trinkle-Mulcahy and A. Lamond (7, 9)), U5 small nuclear ribonucleoprotein particles (snRNPs) p116 and p200 (P. Fabrizio and R. Lührmann, (20, 21)), U2 snRNPs spliceosome-associated protein (SAP) 145 and SAP155 (R. Reed (22, 23)), and myosin heavy chain (M. Walsh (24)).
Proteins were separated by SDS-PAGE, transferred for 300 Vh to nitrocellulose, blocked overnight in 5% (w/v) milk powder in 20 mM Tris-HCl, pH 7, and 500 mM NaCl. Blots were probed for 1 h, washed and incubated for 45 min with appropriate secondary antibody diluted 5,000-fold, and developed with the enhanced chemiluminescence system (Pharmacia). When necessary, blots were quantified using the ImageQuant 5.2 software.
For ZAP immunoprecipitation, 0.25 ml of ZAP crude immune sera or pre-immune sera was incubated with 0.2 ml of protein-A Sepharose, washed and coupled as described (25). Nuclear extract (10 mg) prepared as before plus 5 µg/ml pepstatin was mixed with 0.1 ml of anti-ZAP protein-A Sepharose beads for 2 h at 4 °C, washed three times with 1 ml of phosphate-buffered saline plus 0.1% (v/v) Tween-20, and proteins were solubolized with 100 µl of SDS mixture. For SAP155, 10 µl of crude immune sera was incubated with 0.03 ml of protein-A Sepharose and washed. Nuclear extract (3 mg) was mixed with 0.03 ml of anti-SAP155 protein-A Sepharose beads for 3 h at 4 °C, washed five times with 1 ml of phosphate-buffered saline plus 20 mM NaF, and proteins were solubolized with 50 µl of SDS mixture.
Far Western Analysis
For overlays, PP1
1 was labeled with digoxygenin-3-O-methylcarbonyl-aminocaproic-acid-N-hydroxy-succinamide ester (DIG-PP1) as described (13) and used at the indicated concentration. Proteins were run on SDS-PAGE, transferred to nitrocellulose (300 Vh), and blocked overnight. Blots were probed for 3 h, washed and incubated for 45 min with anti-digoxygenin antibody diluted 10,000-fold (Roche, Indianapolis, IN), and developed with the enhanced chemiluminescence system. In experiments with peptides based on the PP1 binding motif, a peptide was synthesized surrounding the PP1 binding region of human NIPP-1 (26) and constituted residues 191210 (RPKRKRKNSRVTFSEDDEII). The control peptide was identical, except Phe203 was replaced with an alanine, which abolishes PP1 binding to its targeting subunits (15, 26). The peptide GKKRVRWADLE based on the putative PP1 binding site of ZAP was used in PP1 overlays as indicated.
Peptides were synthesized by Denis McMaster (Peptide Synthesis Core Facility, University of Calgary) using N-9-fluorenylmethoxycarbonyl chemistry on an Applied Biosystems 431A peptide synthesizer (Applied Biosystems, Foster City, CA). The peptides were purified by Sephadex G-10 chromatography, and the peptide purity (>90%) and composition was verified by high-pressure liquid chromatography and amino acid analysis, respectively.
Mass Spectrometry
Proteins were electrophoresed on 412% gradient SDS-PAGE, lightly stained with Coomassie blue, and the appropriate band was excised. The protein was in-gel digested with trypsin after alkylation of cysteines with 4-vinyl-pyridine following the method described in Stubbs et al. (27). Tryptic peptides were analyzed on a Perseptive Biosystems (Framingham, MA) Elite STR matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometer with saturated
-cyanocinnamic acid as the matrix. The mass spectrum was acquired in the reflector mode and was internally mass calibrated. The tryptic peptide ions obtained were scanned against the Swiss-Prot, NCBI, and GenPept databases using the MS-FIT program of ProteinProspector (prospector.ucsf.edu) run on a local server. In all cases, the mass tolerance was set at 40 ppm. In some cases, for confirmation of identity or where there was an ambiguity in the identity of a protein sample, liquid chromatography tandem mass spectroscopy (LC-MS/MS) was performed. The tryptic digest was injected on to a 0.075 x 100-mm PepMap C18 capillary column, equilibrated with 0.1% formic acid in water and attached to an LC-Packings Ultimate HPLC system (Dionex, Camberley, UK). The column was developed with a discontinuous acetonitrile gradient at 0.2 µl/min, and the column was interfaced to a Q-TOF2 mass spectrometer (Micromass, Manchester, UK). The peptide ions generated by the electrospray interface were fragmented automatically using machine-defined collision voltages. The resultant peak lists were searched using the Sonar search engine (Genomic Solutions, Ann Arbor, MI) against the NCBI nr database.
| RESULTS |
|---|
|
|
|---|
1. This technique has previously been established as a sensitive method to identify putative PP1 binding proteins (13, 14). The result (Fig. 1B) indicated that many more nuclear PP1 binding proteins exist than have been previously detected (9). To explore this possibility further, protein phosphatases sensitive to microcystin were purified on a microcystin affinity matrix. Like Fig. 1B and previous work (9), the major PP1 binding proteins visualized (Fig. 1C) had molecular masses of 43 and 112 kDa and were later determined to be NIPP-1 and p99/PNUTS, respectively. A longer exposure of the same blot revealed numerous other putative PP1 binding proteins (Fig. 1D). The binding pattern is essentially identical to the crude nuclear extract, indicating that a majority of the nuclear PP1 binding proteins purifies on the microcystin matrix. The binding of PP1 to these proteins could be blocked by inclusion of a peptide based upon the PP1 binding site of the known PP1 regulatory subunit NIPP-1 (Fig. 1, C and D, lane 2). Changing the key binding residue of the peptide, F203 (26), to an alanine re-established this interaction (Fig. 1, C and D, lane 3), suggesting that these proteins are true nuclear PP1 binding proteins and encouraged us to pursue the identity of these proteins. Overlays performed with human PP1
1 gave identical results (data not shown).
|
|
|
1,
2, ß, and
1 were found in the mass ion data. It is possible that PP1
2 is present in the nucleus, but our data is not conclusive; PP1
1 and
2 only differ in a short region in their C termini. The C-terminal tryptic peptide unique to PP1
2 was not present in the mass ion data. Peptides unique to the PP2A A
subunit were identified along with several PP2A-associated proteins belonging to the separate gene families called B and B'. Because of the number and relatedness of the different B and B' subunits, we could not conclusively and unequivocally identify particular gene products. No peptides unique to PP2A Aß were observed. Other protein bands identified include the myosin heavy chain, the U2 snRNPs A', SAP145, SAP155, the U5 snRNPs p116 and p200, a putative RNA binding protein named ZAP, hnRNA binding protein M4, TPR and SH2 phosphoprotein p160, p99, NIPP-1, cdk1, and a putative nudix hydrolase related to syndesmos. We have used antibodies to confirm the specific association of some of these proteins to the microcystin matrix.
|
0.10.2% of the total amount of splicing factor present in a nuclear extract. To confirm the interaction of the U2 snRNPs with a protein phosphatase, we performed a co-immunoprecipitation experiment using the SAP155 antibody. This demonstrated that PP1, but not PP2Ac, was in a complex with the U2 snRNP SAP155 (Fig. 5). The targeting of a protein phosphatase to the splicing machinery is consistent with previous results showing that particular steps of the splicing event are regulated by reversible phosphorylation (2831). The
200-kDa band was identified by LC-MS/MS as myosin. Although myosin does bind nonspecifically to the control matrix, this molecule was consistently enriched 2- to 3-fold on the microcystin matrix for several different preparations (Fig. 4). In light of this result, we then blotted the nuclear extract and microcystin and blank column eluents with antibodies generated against the smooth muscle myosin phosphatase regulatory proteins M110 and M20. No immunoreactive bands for the M20 subunit were seen in the nuclear extract or column eluents. A doublet of
120 kDa and a band of 55 kDa were noted in nuclear extracts and the microcystin-Sepharose eluent for the M110 antibody. Fig. 4J shows the
120-kDa immunoreactive doublet. The 55-kDa band is not shown but is likely the classic M-subunit proteolytic degradation product, which retains the ability to bind PP1 (12). The putative RNA binding protein ZAP was also shown to associate specifically with the affinity matrix (Fig. 4). To further establish an interaction between PP1 and ZAP, we generated ZAP anti-peptide antibodies. Western analysis of nuclear and cytosolic fractions with this serum revealed an immunorecative band the same size as the band identified as ZAP in Fig. 3 (180 kDa) and an additional protein of
240 kDa. Both were localized exclusively to the nucleus (Fig 6A). After immunoprecipitation with the anti-ZAP sera, both the 180- and 240-kDa forms were visualized by Western blotting with the same antibody (data not shown). Blotting the same immunoprecipitation samples also confirmed that PP1, but not PP2Ac, forms a complex with ZAP (Fig. 6B). Far Western experiments show that the 180- and 240-kDa immunoprecipitated ZAP proteins also have the ability to bind PP1 in an overlay, suggesting they form a direct interaction with PP1, and this can be blocked with the ZAP peptide GKKRVRWADLE containing the putative PP1 binding site (Fig. 6C).
|
|
|
| DISCUSSION |
|---|
|
|
|---|
By utilizing immunofluorescence confocal microscopy and isoform-specific antipeptide antibodies, other studies have shown that the PP1 isoforms
, ß, and
1 are present in the nucleus (32), although their serum did not distinguish between PP1
1 and
2 or recognize PP1
2. Trinkle-Mulcahy et al. (7) have shown PP1
1 and
1 to be highly enriched in the nucleolus and nucleoplasm, respectively, using fluorescent PP1 fusion proteins. Our mass spectrometry data confirms that four of the five mammalian PP1 gene products are present in the nucleus. The sole difference between PP1
1 and PP1
2 is a short region on the C terminus that is generated by alternative splicing. The tryptic peptide unique to
1 was identified in our ion mass data, but not the peptide unique to
2. The PP2A A
gene product and what is likely a mixture of B and B' subunits of PP2A were also present in the column eluate.
We have identified a novel protein, previously annotated as ZAP, as a new potential PP1-targeting subunit. This protein purifies on microcystin-Sepharose, binds readily to PP1 in an overlay assay (this association can be blocked by a peptide containing the PP1 binding region; Figs. 1 and 6C), and has a classic PP1 binding motif near its C terminus. This interaction was supported by immunoprecipitating ZAP from a nuclear extract and showing that PP1, and not PP2Ac, co-immunoprecipitates. Furthermore, the immunoprecipitated ZAP binds PP1 in the overlay assay. A compiled list of established PP1 binding proteins and their PP1-interacting sites show that a majority of binding sites conform to the K/R-V/I-X-F/W signature. This list, in conjunction with data from panning a random peptide library with PP1 (16), also reveals a preference for other amino acids at particular positions. Notable is an acidic residue two positions C-terminal to the F/W and a basic residue (usually R or H) between the V/I and F/W site. A string of basic residues often precedes the signature R/K position. The putative PP1 binding site in ZAP fits all this criteria perfectly, and we propose that PP1 interacts with ZAP at the site KKRVRWAD. Furthermore, the peptide GKKRVRWADLE based on this site blocks the binding of PP1 to ZAP (Fig. 6C). Consistent with the idea that this is the PP1 binding region, this motif resides near the C terminus of the protein and likely is positioned on the protein surface and not buried. The function of ZAP in the nucleus is not defined at the moment. Blast, Fasta, and motif searches with the protein sequence reveal that ZAP has regions that display homology to RNA helicases, the viral protein 2C which is an RNA/nucleotide binding protein, adenylate and uridine kinases, 2',3'-cyclic-nucleotide 3'-phosphodiesterase, and several pre-mRNA splicing factors. The ZAP protein contains an abundance of RG motifs and proline-rich domains followed by an arginine/aspartate (RD)-rich region. RG, Pro, and RD-rich motifs have been noted to be present in RNA binding proteins associated with pre-mRNA splicing (33, 34), including snRNP-B', U1 snRNP 70 kDa, SAP49, SAP 62, SF3a 120K, and U2 snRNP A', all of which were identified as having homologous regions in our database searches. Taken together, this information suggests a link of ZAP function to RNA binding/RNA metabolism. Although ZAP has motifs found in many splicing factors, a recent catalogue of the spliceosomal proteins did not identify ZAP (33, 34). Future work will examine the role of targeting PP1 to this nuclear protein.
The splicing of pre-mRNAs into mature mRNA is carried out by a large nuclear protein/RNA complex referred to as the spliceosome, which is composed of at least 145 proteins and five small nuclear RNAs (U1, U2, U4, U5, and U6) (33, 34). There is a stepwise assembly of spliceosomal components onto pre-mRNAs through a recruitment of factors from a nuclear "reservoir" known as speckles (29, 30). The purification of spliceosomes has revealed that the complex is sensitive to salt, and many protein components dissociate in even 200 mM NaCl (35). Considerable evidence has implicated protein (de)phosphorylation with assembly, catalysis, and disassembly of the spliceosome (2831), with particular steps dependent upon PP2C and the okadaic acid-sensitive protein phosphatases (PP1 and PP2A). Western analysis confirmed the MS results that U5 snRNPs p116 and p200 and U2 snRNPs SAP145 and SAP155 are selectively retained on the microcystin affinity matrix. The U2 snRNP A' also appears to be enriched compared with the control matrix. Only
0.10.2% of the nuclear pool of these factors was bound to the matrix, consistent with the idea that only a portion of these factors are actively involved in splicing and that microcystin-sensitive protein phosphatases may only interact transiently with the spliceosome. We performed a co-immunoprecipitation experiment with SAP155 antibodies and demonstrated that PP1 is retained in this complex. This is consistent with a recent report where it was demonstrated that the FHA domain of the nuclear PP1-targeting subunit NIPP-1 associates with SAP155 in a phosphorylation-dependent manner (31). SAP155 is only phosphorylated in functional spliceosomes, and this modification takes place concomitant with or just after the first splicing step of the U2 snRNP (23). This implies that a dephosphorylation event must take place. It is likely that the U2 snRNPs and possibly a larger part of the splicing complex were retained on our affinity matrix due to the association of NIPP-1 with SAP155. The fact that only a selection of splicing factors appear to be enriched on the phosphatase affinity matrix may reflect the association of protein phosphatases with the complex only during specific steps of assembly, catalysis, and disassembly. It is also likely that this is partially due to the salt sensitivity of the splicing machinery complex (35). Our work supports the idea that protein phosphatases are important components of the splicing machinery. To date, mass spectrometric analysis of splicing components and even 145 distinct spliceosomal proteins from the whole complex surprisingly failed to find the association of any protein phosphatase subunits, with the exception of PP2C (33). This is likely due to the fact that protein phosphatase inhibitors have not been used during isolation of the complex. Here, we have incubated the nuclear extracts with a potent phosphatase inhibitor coupled to a matrix. This should abolish all microcystin-sensitive protein phosphatase activity and lock the phospho-status of the extract. No PP1 or PP2A has been isolated with spliceosomal preparations, yet we have purified several splicing components with protein phosphatases, which suggests that these phosphatases may interact transiently with the splicing machinery in a phosphorylation-dependent event. Further work is necessary to define specific roles for protein phosphatases in splicing events and to determine if protein phosphatase regulatory subunits other than NIPP-1 target to the splicing complex.
The nudix hydrolases or nudix pyrophosphatases are a group of enzymes currently thought to play a role in cleansing the cell of nucleoside diphosphate derivatives (36). To date there is no information suggesting the interaction of one of these enzymes with a protein phosphatase (or phosphatase complex) or the specific localization to the nucleus. It is interesting that this enzyme appears to enrich on our matrix (Figs. 2 and 3), and determining if it is associated with a protein phosphatase specifically or if it exists in a phosphatase complex will be an intriguing endeavor.
Myosin, in conjunction with actin, functions as a molecular motor in cells. Myosin has been localized to the nucleus (37), but to our knowledge, this is the first demonstration of a myosin PP1-targeting subunit in the nucleus of the cell and most likely explains the enrichment of myosin on our matrix. Further work is necessary to determine the role of PP1 bound to myosin in the nucleus. Antibodies were not available to determine if all proteins that appeared to be enriched on the microcystin matrix (Table I) are specifically associated or not. These proteins await further studies.
Our overlay method revealed several more PP1 binding proteins with molecular masses between 185 and 250 kDa that are present in the column elution (Fig. 3B). Although mass spectrometry did not determine the
240-kDa protein to be ZAP, Western analysis indicated that this PP1 binding protein is ZAP240. To date, we have been unable to identify these other high-molecular-mass proteins unequivocally, and further work is needed to reveal their identity. We speculate that these, and likely more, lower-abundance PP1 binding proteins are present in the nucleus. Due to the nonspecific binding of protein and likely protein/nucleic acid complexes to Sepharose beads, we have probably reached the limit of the power of microcystin-Sepharose to purify PP1 complexes (Fig. 2) from nuclear extracts. An additional refinement of the technique may be necessary to proceed and further enrich these complexes to identify additional PP1-targeting subunits.
| ACKNOWLEDGMENTS |
|---|
| FOOTNOTES |
|---|
Published, MCP Papers in Press, January 14, 2004, DOI 10.1074/mcp.M300115-MCP200
1 The abbreviations used are: PP1, protein phosphatase 1; PP2A, protein phosphatase 2A; snRNP, small nuclear ribonucleoprotein particle; SAP145, spliceosome-associated protein 145; SAP155, spliceosome-associated protein 155; NIPP-1, nuclear inhibitor protein phosphatase 1; hnRNA, heterogeneous nuclear RNA; MALDI-TOF MS, matrix assisted laser desorption/ionization time-of-flight mass spectrometry; LC-MS/MS, liquid chromatography-tandem mass spectrometry; 2-ME, 2-mercaptoethanol; PMSF, phenylmethylsulfonyl fluoride; NE, nuclear extract; DIG-PP1, digoxygenin-3-O-methylcarbonyl-aminocaproic-acid-N-hydroxy-succinamide ester. ![]()
* Work in G.B.G.M.s laboratory is supported by the Natural Sciences and Engineering Research Council of Canada. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. ![]()
¶ To whom correspondence should be addressed: Department of Biological Sciences, University of Calgary, 2500 University Drive NW, Calgary, Alberta T2N 1N4, Canada. Tel.: 403-220-6238; Fax: 403-289-9311; E-mail: moorhead{at}ucalgary.ca
| REFERENCES |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
A. Massiello, J. R. Roesser, and C. E. Chalfant SAP155 Binds to ceramide-responsive RNA cis-element 1 and regulates the alternative 5' splice site selection of Bcl-x pre-mRNA FASEB J, August 1, 2006; 20(10): 1680 - 1682. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. M. Chen, T. S. Ferrar, E. Lohmeir-Vogel, N. Morrice, Y. Mizuno, B. Berenger, K. K. S. Ng, D. G. Muench, and G. B. G. Moorhead The PII Signal Transduction Protein of Arabidopsis thaliana Forms an Arginine-regulated Complex with Plastid N-Acetyl Glutamate Kinase J. Biol. Chem., March 3, 2006; 281(9): 5726 - 5733. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Trinkle-Mulcahy, J. Andersen, Y. W. Lam, G. Moorhead, M. Mann, and A. I. Lamond Repo-Man recruits PP1{gamma} to chromatin and is essential for cell viability J. Cell Biol., February 27, 2006; 172(5): 679 - 692. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||